This TME remodeling sensitized glioblastoma cells to αPD-L1 therapy (Fig. 7), thus provided a mechanistic basis for CXCR7 activation to enhance anti-tumor immunity that could support immunotherapies. The gene discussed is ACKR3; the disease is glioblastoma.